Esperion Therapeutics reported 400K in Interest Income for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Income Change
Alnylam Pharmaceuticals ALNY:US 1.9M 887K
Biogen BIIB:US 12.6M 9.7M
BioMarin Pharmaceutical BMRN:US 2.5M 685K
Cytokinetics CYTK:US 864K 449K
Eli Lilly LLY:US 10.2M 3.2M
Esperion Therapeutics ESPR:US 400K 100K
Geron GERN:US 330K 218K
Intra Cellular Therapies ITCI:US 1.32M 772K
Moderna Inc MRNA:US 40M 25M
Nektar Therapeutics NKTR:US 1.1M 701K
Pfizer PFE:US 30M 16M
Puma Biotechnology PBYI:US 65K 52K
Sarepta Therapeutics SRPT:US 2.41M 2.24M
United Therapeutics UTHR:US 6.8M 2.5M